RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $576
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Ben Hendrix maintains an Outperform rating on Chemed (NYSE:CHE) but lowers the price target from $610 to $576.
July 31, 2023 | 2:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Chemed's price target has been lowered from $610 to $576 by RBC Capital, though the Outperform rating is maintained.
While the lowering of the price target might initially seem negative, the maintenance of the Outperform rating indicates that RBC Capital still sees strong potential in Chemed. This could lead to mixed market reactions in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100